Clinical Trials Logo

ER+ and AR+ Breast Cancer clinical trials

View clinical trials related to ER+ and AR+ Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02746328 Withdrawn - Clinical trials for ER+ and AR+ Breast Cancer

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.

NCT ID: NCT02463032 Completed - Clinical trials for ER+ and AR+ Breast Cancer

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.